Results 21 to 30 of about 12,698 (210)

Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study

BMC Endocrine Disorders, 2020
Background Whether lower dose cabergoline therapy for hyperprolactinemia increases risk of valvular dysfunction remains controversial. We examined valvular abnormalities among asymptomatic adults with hyperprolactinemia treated with dopamine agonists ...
Amer Budayr, Thida C. Tan, Joan C. Lo, Jonathan G. Zaroff, Grace H. Tabada, Jingrong Yang, Alan S. Go   +6 more
doaj   +1 more source

Rapid and dramatic glucose‐lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma

Journal of Diabetes Investigation, 2021
Dopamine receptor agonists are typically used to treat Parkinson’s disease and certain pituitary tumors, such as prolactinoma or a growth hormone‐producing tumor.
Motoyuki Igata, Yoshitaka Yagi, Satoko Hanatani, Masaji Sakaguchi, Norio Ishii, Kayo Yoshinaga, Junji Kawashima, Hiroyuki Motoshima, Eiichi Araki   +8 more
doaj   +1 more source

Effect of bromocriptine on glycemic control, risk of cardiovascular diseases and weight in patients with type 2 diabetes: a systematic review

Diabetology & Metabolic Syndrome, 2023
Background Type 2 diabetes (T2DM) patients, including those in good glycemic control, have an increased risk of cardiovascular disease (CVD). Maintaining good glycemic control with drugs may reduce long-term CVD risk.
Mulualem Tesfaye Birhan, Teklie Mengie Ayele, Fikire Wondimu Abebe, Fiseha Nigussie Dgnew   +3 more
doaj   +1 more source

Bromocriptine and insulin sensitivity in lean and obese subjects

Endocrine Connections, 2016
Bromocriptine is a glucose-lowering drug, which was shown to be effective in obese subjects with insulin resistance. It is usually administered in the morning. The exact working mechanism of bromocriptine still has to be elucidated.
L Bahler, H J Verberne, E Brakema, R Tepaske, J Booij, J B Hoekstra, F Holleman   +6 more
doaj   +1 more source

Effects of Bromocriptine on Glucose and Insulin Dynamics in Normal and Insulin Dysregulated Horses

Frontiers in Veterinary Science, 2022
The objectives of the study were to study the effects of the synthetic ergot alkaloid (EA), bromocriptine, on glucose and lipid metabolism in insulin dysregulated (ID, n = 7) and non-ID (n = 8) mares. Horses were individually housed and fed timothy grass
Caroline M. M. Loos, Kristine L. Urschel, Eric S. Vanzant, Erin L. Oberhaus, Adam D. Bohannan, James L. Klotz, Kyle R. McLeod   +6 more
doaj   +1 more source

Circadian‐timed quick‐release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitus

Endocrinology, Diabetes & Metabolism, 2020
Objective Sympathetic nervous system (SNS) overactivity is a risk factor for insulin resistance and cardiovascular disease (CVD). We evaluated the impact of bromocriptine‐QR, a dopamine‐agonist antidiabetes medication, on elevated resting heart rate (RHR)
Bindu Chamarthi, Aaron Vinik, Michael Ezrokhi, Anthony H. Cincotta   +3 more
doaj   +1 more source

Therapeutic activity of sarpogrelate and dopamine D2 receptor agonists on cardiovascular and renal systems in rats with alloxan-induced diabetes

BMC Pharmacology and Toxicology, 2021
Background Dopamine D2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia.
Mohammed Ahmed Fouad Shalaby, Hekma A. Abd El Latif, Mohamed El Yamani, May Ahmed Galal, Sherifa Kamal, Ikhlas Sindi, Raneem Masaood   +6 more
doaj   +1 more source

A case of Parkinson's disease associated with bromocriptine - induced leukopenia and throm-bocytopenia [PDF]

, 2003
症例は67歳,女性｡以前からパーキンソン病にて加療されていたが,リハビリテーション目的で当院入院した.入院時白血球数,血小板数正常であったが,bromocriptine投与開始後白血球減少,血小板減少を認めた.薬剤性白血球減少症及び血小板減少症を疑い, bromocriptine投与中止するとともにfilgrastim投与により,白血球減少,血小板減少は改善した。誘発試験施行し白血球減少を認めた｡Bromocriptineによる白血球減少症,血小板減少症の報告は少なく ...
Hosaki, Yasuhiro, Tanizaki, Yoshiro, Tanimoto, Mitsune, Okamoto, Makoto, Ashida, Kozo, Takata, Shingo, Nishida, Norikazu, Yokoi, Tadashi, Mitsunobu, Fumihiro, Niiya, Kenji, Mifune, Takashi, Tsugeno, Hirofumi   +11 more
core   +1 more source

Dopaminergic agonist bromocriptin in treatment of diabetes mellitus type 2

Ожирение и метаболизм, 2011
Bromocriptine is a sympatholytic agonist of dopamine receptors, which is now proposed for treatment of type 2 diabetes mellitus. In animal studies bromocriptine elevates the decreased levels of dopamine in hypothalamus and blocks excessive sympathetic ...
O. A. Gerasimenko, E. A. Pigarova, L. K. Dzeranova   +2 more
doaj   +1 more source

Bromocriptine mesylate: Food and Drug Administration approved new approach in therapy of non-insulin dependant diabetes mellitus with poor glycemic control

Journal of Pharmacy and Bioallied Sciences, 2010
Food and Drug Administration (FDA) approved bromocriptine mesylate, a quick release formulation, 0.8 mg tablets, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Yogendra Keche
doaj   +1 more source